Cassava Sciences Inc SAVA
Institutional shares held
14 Million
2.98M
calls
6.57M
puts
Total value of holdings
$391M
$83.4M
calls
$184M
puts
Market Cap
$1.12B
40,097,900
Shares Out.
Institutional ownership
34.83%
# of Institutions
207
We take great care to ensure that the data presented and summarized in this overview for CASSAVA SCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SAVA
View all-
Black Rock Inc. New York, NY3.22MShares$90.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$70.6 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$32.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$28.2 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$16.2 Million7.83% of portfolio
-
Morgan Stanley New York, NY520KShares$14.5 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL396KShares$11.1 Million0.0% of portfolio
-
Toroso Investments, LLC Massapequa, NY375KShares$10.5 Million0.13% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA362KShares$10.1 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA306KShares$8.58 Million0.0% of portfolio
Latest Institutional Activity in SAVA
Top Purchases
Top Sells
About SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Transactions at SAVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
Sanford Robertson Director |
BUY
Bona fide gift
|
Indirect |
5,000
+50.0%
|
-
|
|
May 16
2024
|
Sanford Robertson Director |
SELL
Bona fide gift
|
Direct |
5,000
-0.52%
|
-
|
|
Apr 26
2024
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69,000
+6.73%
|
$1,518,000
$22.0 P/Share
|
|
Apr 23
2024
|
Richard Barry President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
176,085
+27.27%
|
$3,873,870
$22.0 P/Share
|
|
Apr 18
2024
|
James William Kupiec Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+27.27%
|
$33,000
$22.0 P/Share
|
|
Apr 17
2024
|
Eric Schoen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+6.58%
|
$33,000
$22.0 P/Share
|
|
Aug 23
2023
|
Sanford Robertson Director |
BUY
Open market or private purchase
|
Direct |
30,000
+3.27%
|
$510,000
$17.45 P/Share
|
|
Aug 22
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
16,571
+5.34%
|
$265,136
$16.65 P/Share
|
|
Aug 21
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
1,906
+0.68%
|
$30,496
$16.8 P/Share
|
|
Jun 12
2023
|
Patrick J Md Phd Scannon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$0
$0.95 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
47,723
-6.1%
|
$1,193,075
$25.25 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
71,428
+8.37%
|
$1,142,848
$16.87 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
9,545
-2.44%
|
$238,625
$25.25 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,285
+3.53%
|
$228,560
$16.87 P/Share
|
|
May 10
2023
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,284
+0.36%
|
$157,828
$17.64 P/Share
|
|
May 01
2023
|
Robert Z Gussin Director |
BUY
Payment of exercise price or tax liability
|
Direct |
7,077
+40.0%
|
$162,771
$23.34 P/Share
|
|
May 01
2023
|
Robert Z Gussin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,284
+17.95%
|
$157,828
$17.64 P/Share
|
|
Mar 07
2023
|
Michael J O Donnell Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,139
-24.22%
|
$128,475
$25.2 P/Share
|
|
Mar 07
2023
|
Michael J O Donnell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,142
+26.32%
|
$128,556
$18.13 P/Share
|
|
Mar 07
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
77,276
+21.94%
|
$1,931,900
$25.76 P/Share
|
Last 12 Months Summary
Buy / Acquisition
253K
Shares
From
5
Insiders
| Bona fide gift | 5K shares |
|---|---|
| Exercise of conversion of derivative security | 248K shares |
Sell / Disposition
5K
Shares
From
1
Insiders
| Bona fide gift | 5K shares |
|---|